192 related articles for article (PubMed ID: 22014002)
1. Chitotriosidase as a biomarker of cerebral adrenoleukodystrophy.
Orchard PJ; Lund T; Miller W; Rothman SM; Raymond G; Nascene D; Basso L; Cloyd J; Tolar J
J Neuroinflammation; 2011 Oct; 8():144. PubMed ID: 22014002
[TBL] [Abstract][Full Text] [Related]
2. [X-linked adrenoleukodystrophy].
Aubourg P
Ann Endocrinol (Paris); 2007 Dec; 68(6):403-11. PubMed ID: 17532287
[TBL] [Abstract][Full Text] [Related]
3. Metformin-induced mitochondrial function and ABCD2 up-regulation in X-linked adrenoleukodystrophy involves AMP-activated protein kinase.
Singh J; Olle B; Suhail H; Felicella MM; Giri S
J Neurochem; 2016 Jul; 138(1):86-100. PubMed ID: 26849413
[TBL] [Abstract][Full Text] [Related]
4. Treatment of cerebral adrenoleukodystrophy: allogeneic transplantation and lentiviral gene therapy.
Gupta AO; Raymond G; Pierpont EI; Kemp S; McIvor RS; Rayannavar A; Miller B; Lund TC; Orchard PJ
Expert Opin Biol Ther; 2022 Sep; 22(9):1151-1162. PubMed ID: 36107226
[TBL] [Abstract][Full Text] [Related]
5. Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's oil".
van Geel BM; Assies J; Haverkort EB; Koelman JH; Verbeeten B; Wanders RJ; Barth PG
J Neurol Neurosurg Psychiatry; 1999 Sep; 67(3):290-9. PubMed ID: 10449548
[TBL] [Abstract][Full Text] [Related]
6. The effect of Lorenzo's oil on oxidative stress in X-linked adrenoleukodystrophy.
Deon M; Wajner M; Sirtori LR; Fitarelli D; Coelho DM; Sitta A; Barschak AG; Ferreira GC; Haeser A; Giugliani R; Vargas CR
J Neurol Sci; 2006 Sep; 247(2):157-64. PubMed ID: 16750542
[TBL] [Abstract][Full Text] [Related]
7. Retrospective evaluation of patients with X-linked adrenoleukodystrophy with a wide range of clinical presentations: a single center experience.
Olgac A; Kasapkara ÇS; Derinkuyu B; Yüksel D; Çetinkaya S; Aksoy A; Ceylaner S; Güleray N; Yeşilipek A; Aydın Hİ; Orgun LT; Kılıç M
J Pediatr Endocrinol Metab; 2021 Sep; 34(9):1169-1179. PubMed ID: 34162029
[TBL] [Abstract][Full Text] [Related]
8. Decreased expression of ABCD4 and BG1 genes early in the pathogenesis of X-linked adrenoleukodystrophy.
Asheuer M; Bieche I; Laurendeau I; Moser A; Hainque B; Vidaud M; Aubourg P
Hum Mol Genet; 2005 May; 14(10):1293-303. PubMed ID: 15800013
[TBL] [Abstract][Full Text] [Related]
9. X-linked adrenoleukodystrophy: role of very long-chain acyl-CoA synthetases.
Jia Z; Pei Z; Li Y; Wei L; Smith KD; Watkins PA
Mol Genet Metab; 2004; 83(1-2):117-27. PubMed ID: 15464426
[TBL] [Abstract][Full Text] [Related]
10. Adrenoleukodystrophy in the Differential Diagnosis of Boys Presenting with Primary Adrenal Insufficiency without Adrenal Antibodies.
Ryalls MR; Gan HW; Davison JE
J Clin Res Pediatr Endocrinol; 2021 Jun; 13(2):212-217. PubMed ID: 32394691
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid matrix metalloproteinases are elevated in cerebral adrenoleukodystrophy and correlate with MRI severity and neurologic dysfunction.
Thibert KA; Raymond GV; Nascene DR; Miller WP; Tolar J; Orchard PJ; Lund TC
PLoS One; 2012; 7(11):e50430. PubMed ID: 23185624
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of pharmacological induction of fatty acid beta-oxidation in X-linked adrenoleukodystrophy.
McGuinness MC; Zhang HP; Smith KD
Mol Genet Metab; 2001; 74(1-2):256-63. PubMed ID: 11592822
[TBL] [Abstract][Full Text] [Related]
13. Targeted inactivation of the X-linked adrenoleukodystrophy gene in mice.
Forss-Petter S; Werner H; Berger J; Lassmann H; Molzer B; Schwab MH; Bernheimer H; Zimmermann F; Nave KA
J Neurosci Res; 1997 Dec; 50(5):829-43. PubMed ID: 9418970
[TBL] [Abstract][Full Text] [Related]
14. Intensity of MRI Gadolinium Enhancement in Cerebral Adrenoleukodystrophy: A Biomarker for Inflammation and Predictor of Outcome following Transplantation in Higher Risk Patients.
Miller WP; Mantovani LF; Muzic J; Rykken JB; Gawande RS; Lund TC; Shanley RM; Raymond GV; Orchard PJ; Nascene DR
AJNR Am J Neuroradiol; 2016 Feb; 37(2):367-72. PubMed ID: 26427835
[TBL] [Abstract][Full Text] [Related]
15. Therapy of X-linked adrenoleukodystrophy.
Semmler A; Köhler W; Jung HH; Weller M; Linnebank M
Expert Rev Neurother; 2008 Sep; 8(9):1367-79. PubMed ID: 18759549
[TBL] [Abstract][Full Text] [Related]
16. Glycoprotein nonmetastatic melanoma protein B (GNMPB) as a novel biomarker for cerebral adrenoleukodystrophy.
Taghizadeh LA; King CJ; Nascene DR; Gupta AO; Orchard PJ; Higgins L; Markowski TW; Nolan EE; Furcich JW; Lund TC
Sci Rep; 2022 May; 12(1):7985. PubMed ID: 35568699
[TBL] [Abstract][Full Text] [Related]
17. Comparison of C26:0-carnitine and C26:0-lysophosphatidylcholine as diagnostic markers in dried blood spots from newborns and patients with adrenoleukodystrophy.
Huffnagel IC; van de Beek MC; Showers AL; Orsini JJ; Klouwer FCC; Dijkstra IME; Schielen PC; van Lenthe H; Wanders RJA; Vaz FM; Morrissey MA; Engelen M; Kemp S
Mol Genet Metab; 2017 Dec; 122(4):209-215. PubMed ID: 29089175
[TBL] [Abstract][Full Text] [Related]
18. Successful donor engraftment and repair of the blood-brain barrier in cerebral adrenoleukodystrophy.
Orchard PJ; Nascene DR; Miller WP; Gupta A; Kenney-Jung D; Lund TC
Blood; 2019 Mar; 133(12):1378-1381. PubMed ID: 30635285
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of chitotriosidase enzyme activity in nephropathic cystinosis.
Elmonem MA; Makar SH; van den Heuvel L; Abdelaziz H; Abdelrahman SM; Bossuyt X; Janssen MC; Cornelissen EA; Lefeber DJ; Joosten LA; Nabhan MM; Arcolino FO; Hassan FA; Gaide Chevronnay HP; Soliman NA; Levtchenko E
Orphanet J Rare Dis; 2014 Nov; 9():155. PubMed ID: 25407738
[TBL] [Abstract][Full Text] [Related]
20. Isoprostanoid Plasma Levels Are Relevant to Cerebral Adrenoleukodystrophy Disease.
Signorini C; De Felice C; Durand T; Galano JM; Oger C; Leoncini S; Hayek J; Lee JC; Lund TC; Orchard PJ
Life (Basel); 2022 Jan; 12(2):. PubMed ID: 35207434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
